Weekly Round Up

The Healthcare Cost Curve Is Heading the Wrong Way

Rising medical costs are tightening healthcare economics just as capital concentrates in North American VC and LEO Pharma puts $435M behind its next growth opportunity in EPP.

Healthcare PE Gets More Selective: Where Capital Is Concentrating

Behavioral health, biosensors and biotech are attracting capital—but execution is becoming the real differentiator.

Healthcare’s Recovery Gets More Selective

Payers stabilize, dealmaking accelerates, and investors turn their attention to margins.

Healthcare Is Getting Smarter — And Riskier

AI, digital biomarkers, regulation and cybersecurity are reshaping healthcare — and the investment landscape.

Hospital Margins Tighten as Uninsured Patients Rise

Healthcare is becoming increasingly polarized: capital, patients, and AI adoption are flowing toward the strongest platforms.

Healthcare M&A Finds Discipline. Digital Health Finds Momentum

M&A’s discipline in the Americas, quarterly healthtech VC value segmented & digital health finding its foot again.

Why Digital Health Still Can't Scale Enterprise Wide

What prevents digital health companies from achieving enterprise scale, measles cases going through the roof in the US.

The Aging Economy Is Reshaping Healthcare

AI Is Making Healthcare Easier to Build and Harder to Defend

Digital health funding rebounds, Samsung Biologics makes a $1.8B peptide bet, and India looks to become a global healthcare innovation engine.

Healthcare's Capital Is Getting More Selective

Biopharma IPOs reopen, AI reshapes digital health, and margins come under pressure.

The $7B Healthcare Bet + AI’s Next Platform Layer

AI decision support, specialty pharmacy & outbreak detection.

Healthcare's Next $190B Opportunity

GLP-1s are evolving into a multi-disease platform, AI is reshaping pharma operations, and healthcare is regaining investor momentum.